Kabra Drugs P/E Ratio
Current P/E Ratio
10.97
Low Valuation
Low - May indicate good value opportunity
Kabra Drugs (KABRADG) P/E ratio is 10.97 (Low), EPS (TTM) ₹2.09, current price ₹22.84 on BSE — Low - May indicate good value opportunity. See KABRADG price to book ratio to compare market price against book value per share.
Current Valuation Metrics
P/E Ratio
10.97
Current Price
₹22.84
EPS (TTM)
₹2.09
Exchange
BSE
Valuation Signal
Signal
Undervalued
Sector Context
Sector Average
55.48
Sector Median
31.4
Sector Rank
#11 of 194
Sector Percentile
5.7%
KABRADG P/E Ratio — Valuation Signal & Historical Context
Kabra Drugs P/E 10.97 — signal: Undervalued. Read Kabra Drugs dividend policy for the complete payout history and dividend yield track record.
- Stock appears undervalued with PE of 10.97, suggesting potential buying opportunity
- Trading at discount to sector average PE of 55.48
KABRADG vs Healthcare Peers — P/E Ratio Comparison
Kabra Drugs P/E 10.97 vs Healthcare average 55.48, median 31.4 — range 2.86–987.08.
Sector Average
55.48
Sector Median
31.4
Lowest P/E
2.86
Highest P/E
987.08
Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.65 | ₹29 | Low |
| Phaarmasia | PHRMASI | 3.84 | ₹68 | Low |
| JFL Life Sciences | JFLLIFE | 4.64 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.69 | ₹7,502 | Low |
| Shelter Pharma | SHELTER | 5.32 | ₹50 | Low |
| Mono Pharmacare | MONOPHARMA | 6.02 | ₹19 | Low |
| Royal Sense | ROYAL | 7.4 | ₹51 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹79 | Low |
| Amwill Health Care | AMWILL | 7.71 | ₹88 | Low |